Moors & Cabot’s Traws Pharma TRAW Stock Holding History

Moors & Cabot’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-173	Closed	-$65K	–	878
2021 Q1	$65K	Buy	+173	New	+$65.3K	0.01%	741

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Moors & Cabot's TRAW Position: Q2 2021 in Review

Moors & Cabot sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 173 shares — an estimated $65K sold.

Moors & Cabot first reported a position in TRAW in Q1 2021 and held it in 1 quarter. The position peaked at $65K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

Moors & Cabot reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
Moors & Cabot sold 173 Traws Pharma shares in Q2 2021, an estimated $65K.
Moors & Cabot first reported a position in Traws Pharma in Q1 2021 and held it in 1 quarter.
Moors & Cabot's Traws Pharma position peaked at $65K in Q1 2021.
25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Moors & Cabot's 13F filing for Q2 2021, filed 10 Aug 2021.